|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200057537 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-14 16:26:47 |
|
注册时间: Date of Registration: |
2022-03-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请与我们联系完善测量指标信息。 珂立苏治疗新生儿急性呼吸窘迫综合征有效性、安全性评估及其最佳用药剂量探索的真实世界研究 |
|
Public title: |
Real-world study on the effectiveness, safety assessment and optimal dose exploration of neonatal acute respiratory distress syndrome |
|
注册题目简写: |
珂立苏治疗新生儿急性呼吸窘迫综合征有效性、安全性评估及其最佳用药剂量探索的真实世界研究 |
|
English Acronym: |
Real-world study on the effectiveness, safety assessment and optimal dose exploration of neonatal acute respiratory distress syndrome |
|
研究课题的正式科学名称: |
珂立苏治疗新生儿急性呼吸窘迫综合征有效性、安全性评估及其最佳用药剂量探索的真实世界研究 |
|
Scientific title: |
Real-world study on the effectiveness, safety assessment and optimal dose exploration of neonatal acute respiratory distress syndrome |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
韩玉杰 |
研究负责人: |
李晓莺 |
|
Applicant: |
Yujie Han |
Study leader: |
Xiaoying Li |
|
申请注册联系人电话: Applicant telephone: |
18754146336 |
研究负责人电话:
Study leader's |
18754146336 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
410358192@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
410358192@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市槐荫区经十路23976号 |
研究负责人通讯地址: |
山东省济南市槐荫区经十路23976号 |
|
Applicant address: |
山东省济南市槐荫区经十路23976号 |
Study leader's address: |
山东省济南市槐荫区经十路23976号 |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学附属儿童医院 |
||
|
Applicant's institution: |
正式员工 |
||
|
研究负责人所在单位: |
山东大学附属儿童医院 |
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SDFE-ILB/P-2022005 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
济南市儿童医院伦理委员会 |
||
|
Name of the ethic committee: |
济南市儿童医院伦理委员会 |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-02-21 00:00:00 | ||
|
伦理委员会联系人: |
张乐海 |
||
|
Contact Name of the ethic committee: |
韩玉杰 |
||
|
伦理委员会联系地址: |
山东省济南市槐荫区经十路23976号 |
||
|
Contact Address of the ethic committee: |
山东省济南市槐荫区经十路23976号 |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
18754146336 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
410358192@qq.com |
|
研究实施负责(组长)单位: |
济南市儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinan Children's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市槐荫区经十路23976号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.23976, Jing 10 Road, Huaiyin District, Jinan City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
济南市健康与疾病临床医学研究中心 |
||||||||||||||||||||||
|
Source(s) of funding: |
Jinan Health and Disease Clinical Medical Research Center |
||||||||||||||||||||||
|
研究疾病: |
新生儿急性呼吸窘迫综合征 |
||||||||||||||||||||||
|
Target disease: |
新生儿急性呼吸窘迫综合征 |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
关于珂立苏治疗新生儿急性呼吸窘迫综合征的研究较少,样本量小,关于其在真实世界应用中的有效性、安全性的研究更少,且其在真实世界应用中的最佳剂量、使用时间等尚不明确。故本研究拟前瞻性收集全国24家三级医院2022年3月至2024年3月关于ARDS的诊疗数据,(1)评价珂立苏在真实诊疗环境中治疗新生儿急性呼吸窘迫综合征的有效性和安全性;(2)探索不同剂量珂立苏的疗效以及影响其疗效的因素;(3)探索珂立苏治疗新生儿急性呼吸窘迫综合征的最佳剂量。 |
||||||||||||||||||||||
|
Objectives of Study: |
There are few studies on the treatment of neonatal acute respiratory distress syndrome, small sample size, fewer studies on its effectiveness and safety in real-world applications, and its optimal dose and duration of use in real-world applications are unclear.Therefore, this study intends to prospectively collect data on ARDS in 24 tertiary hospitals from March 2022 to March 2024, (1) evaluate the effectiveness and safety of Colisu in real diagnosis and treatment environment; (2) explore the efficacy of different doses of Colisu and the factors affecting its efficacy; and (3) explore the optimal dose of Colisu in the treatment of neonatal ARDS. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
选取全国三级医院新生儿病房,并可应用机械通气治疗的24家综合医院、妇幼保健院及儿童医院组成“全国新生儿 ARDS研究协作组”,选择 2022 年 03月至 2024 年 03月各协作医院收治的符合选入排除标准的患者为前瞻性研究的对象,收集其相应临床数据资料并填写相应调查表。 |
||||||||||||||||||||||
|
Inclusion criteria |
Select the national tertiary hospital neonatal ward, and can apply mechanical ventilation treatment of 24 general hospitals, maternal and child health care and children's hospital "national neonatal ARDS research collaboration group", choose March 2022 to 2024 patients meet the exclusion criteria for prospective study, collect the corresponding clinical data and fill in the corresponding questionnaire. |
||||||||||||||||||||||
|
排除标准: |
1.排除新生儿呼吸窘迫综合征(RDS)、新生儿暂时性呼吸增快(TTN)、肺表面活性物质(PS)相关遗传性缺陷或先天性畸形等引起的呼吸困难; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Excluding respiratory difficulties caused by neonatal respiratory distress syndrome (RDS), neonatal temporary respiratory acceleration (TTN), pulmonary surfactant (PS) -related genetic defects or congenital malformations; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-03-01 00:00:00至 To 2024-02-29 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-03-01 00:00:00 至 To 2024-02-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
no |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
http://172.16.1.31:8080/ARDSmanage |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://172.16.1.31:8080/ARDSmanage |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
http://172.16.1.31:8080/ARDSmanage |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
http://172.16.1.31:8080/ARDSmanage |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |